Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 6/20 | 0.43 |
| ▸ | EIF2AK1 | Q9BQI3 | 8/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | SMOX | Q9NWM0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31594086 | 0.94 | CXCR2 (0.47) | CXCR2EIF2AK1LMNACXCR1KDM1A | |
| SCHEMBL31594246 | 0.90 | CXCR2 (0.45) | CXCR2LMNACXCR1SLC6A2SLC6A4 | |
| SCHEMBL31594238 | 0.89 | CXCR2 (0.42) | CXCR2LMNACXCR1SLC6A2SLC6A4 | |
| SCHEMBL31594090 | 0.88 | CXCR2 (0.43) | CXCR2CXCR1KDM1ARCOR1 | |
| SCHEMBL31594557 | 0.87 | CXCR2 (0.43) | CXCR2CXCR1KDM1ARCOR1SLC6A2 | |
| SCHEMBL31594300 | 0.87 | CXCR2 (0.40) | CXCR2LMNACXCR1SLC6A2SLC6A4 | |
| SCHEMBL31594374 | 0.86 | CXCR2 (0.43) | CXCR2CXCR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31594294 | 0.86 | CXCR2 (0.43) | CXCR2CXCR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31594364 | 0.85 | CXCR2 (0.46) | CXCR2LMNACXCR1SLC6A2SLC6A4 | |
| SCHEMBL31594646 | 0.85 | CXCR2 (0.47) | CXCR2ABL1LMNACXCR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | MRGPRX2, MRGPRX1, MRGPRX4 | CXCR2 763/4885EIF2AK1 4374/4885ABL1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.